Innolake Biopharma

Innolake Biopharma is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines for oncology and autoimmune diseases. Headquartered in Hangzhou, China, the company was founded in 2020 by industry veteran Dr. Robert Zhang, who previously led R&D at Hengrui Medicine. Innolake utilizes its proprietary technology platforms to advance a robust pipeline featuring antibody-drug conjugates (ADCs), bispecific antibodies, and novel small molecules. The company's lead assets, including a PD-L1/CD47 bispecific antibody and a Claudin 18.2 ADC, are currently undergoing clinical evaluation. With strong backing from top-tier venture capital firms, Innolake is positioned to become a leader in the next generation of precision medicine.